Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02853266
Other study ID # 69HCL16_0477
Secondary ID
Status Active, not recruiting
Phase N/A
First received July 21, 2016
Last updated July 28, 2016
Start date September 2011
Est. completion date December 2016

Study information

Verified date July 2016
Source Hospices Civils de Lyon
Contact n/a
Is FDA regulated No
Health authority France: Commission nationale de l'informatique et des libertés
Study type Observational

Clinical Trial Summary

Kawasaki disease (KD) is an acute systemic vasculitic syndrome with coronary tropism. It has been reported worldwide, but it is ten times more common in Asian population. It is the second vasculitis of the child by its frequency after rheumatoid purpura. It occurs in 80% of cases between 1 and 5 years, with a maximal incidence around the age of 12 months.

KD is not well understood and the cause is yet unknown. It may be an autoimmune disorder. The problem affects the mucous membranes, lymph nodes, walls of the blood vessels, and the heart.The clinical picture of KD associate a persistent fever and an antipyretics resistance with mucocutaneous signs and bulky cervical lymphadenopathy usually unilateral.

There is currently no vaccine available against Kawasaki disease so it is extremely important to be able to recognize symptoms before they set in and become too severe.

Chagas disease (CD) is caused by the parasite Trypanosoma cruzi. Acute CD occurs immediately after infection, may last up to a few weeks or months. Infection may be mild or asymptomatic. There may be fever or swelling around the site of inoculation, and acute infection may result in severe inflammation of the heart muscle. The notion that the pathology of CD has an autoimmune component was initially based on the finding of circulating antibodies binding heart tissue antigens in patients chronically infected with T. cruzi.

A recent study reports a possible antigen (non-cruzi-related antibody NCRA) mimicry characterized by a serological reactivity to a well-defined T. cruzi antigen in blood samples from individuals not exposed to the parasite. The measured seroprevalence of such cross-reactivity is in favor of a highly prevalent immunogen acquired in childhood.

There are similarities in mechanism of CD and KD: it could be interesting to explore the presence of NCRA in blood samples from adults with a history of KD.

The objective of the study is the measurement of the biomarker NCRA in serum in adults with a history of KD compare to a control population. This measurement and the prevalence may permit to associate the NCRA to a possible pathogenic agent.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 75
Est. completion date December 2016
Est. primary completion date December 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- History of KD before the age of 18, with or without macroscopic coronary lesions in the childhood phase. (KD group only)

- 18 years old or older at the time of the study.

- Agree on participating to all explorations of the study.

- Accept genotyping.

- Absence of cardiovascular risk factors

Exclusion Criteria:

- - Atypical KD (KD group only)

- Documented or suspected coronary ischemia,

- Refusal to participate to the study or sign the consent

- Contra-indication to the injection of iodinated contrast agents (allergy, renal failure)

- Hypersensitivity to dobutamine,

- No effective contraception method for females with child bearing potential,

- Breastfeeding, or pregnant females,

- Treatment modifying endothelial reactivity

- History of severe intolerance to iodinated contrast agents,

- Subjects who can't hold their breath for at least 20 seconds,

- Irregular or absence of sinus rhythm, especially atrial or ventricular arrhythmia

- Unability to give information to the subject,

- No coverage from a Social Security system

- Deprivation of civil rights

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Other:
laboratory biomarker analysis
Archived serum samples are analysed for measurement of biomarker NCRA

Locations

Country Name City State
France Hôpital Louis Pradel - Service de Pharmacologie Clinique Bron

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence of NCRA in the KD population vs control population. at recruitment time. (Day 0) No
Primary NCRA concentration in the KD population vs control population. Measurement of the biomarker NCRA in serum in adults with a history of KD vs control population at recruitment time. (Day 0) No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05911386 - Multiparametric Echocardiography and Cardiac Biomarkers in Pediatric Inflammatory Heart Diseases
Recruiting NCT02951234 - A Multi-center, Randomized to Compare the Efficacy of IVIG Alone and IVIG Plus High-dose Aspirin in Kawasaki Disease N/A
Active, not recruiting NCT04747847 - Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease Early Phase 1
Withdrawn NCT04535518 - Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease Phase 3
Recruiting NCT01917721 - Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease Phase 2
Recruiting NCT04656184 - A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment Phase 3
Recruiting NCT03200561 - A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study) Phase 3
Completed NCT01440075 - Prevalence and Early Markers of Atherosclerosis in Adults With a History of Kawasaki Disease N/A
Completed NCT02179853 - Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease Phase 1/Phase 2
Withdrawn NCT02980263 - Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease Phase 2
Enrolling by invitation NCT02359643 - Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease N/A
Recruiting NCT04278404 - Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Completed NCT00841789 - A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease Phase 2
Completed NCT00760435 - Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease Phase 3
Not yet recruiting NCT05643651 - Rivaroxaban for Children With Giant Coronary Artery Aneurysms After Kawasaki Disease Phase 4
Recruiting NCT02114099 - Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease Phase 2
Not yet recruiting NCT05091229 - A Blood Test to Diagnose Kawasaki Disease
Completed NCT01431105 - Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities Phase 1/Phase 2
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting NCT06305611 - European and North Indian Cohort of KaWasaki dIsease